Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia
- Staphylococcus Aureus Endocarditis
- Staphylococcus Aureus Septicemia
- Staphylococcus Aureus Bloodstream Infection
At a glance
- Phase
- Phase 4
- Study type
- Interventional
- Sponsor
- Todd C. Lee MD MPH FIDSA
- Enrolment target
- 300
- Started
- 15 January 2026
- Main results due
- January 2030
- Study sites
- 3
- Registry updated
- 24 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
The participant must meet all inclusion and exclusion criteria for the SNAP Platform (NCT05137119) and also the following inclusion and exclusion criteria: Inclusion Criteria: * Patient is taking aspirin for secondary prevention of cardiovascular disease (coronary, cerebrovascular, or peripheral vascular disease) Exclusion Criteria: * Active bleeding (allowing up to 3 days from platform entry to randomize in the event anti-thrombotic therapy is resumed) * Anticipated major cardiac surgery, neurosurgery, or spine surgery within the next 3 days * Pregnancy or lactation * Known receipt of clopidogrel, prasugrel, or ticagrelor within the last month * Allergy to clopidogrel * Concomitant receipt of oral Xa inhibitor or dabigatran
What this study is about
In the sponsor’s own words, from the registry.
This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking aspirin for secondary prevention of cardiovascular events. We will randomize patients to continue their aspirin or change clopidogrel which is also approved for secondary prevention.
Unlike aspirin, clopidogrel may have activity against S. aureus. We wish to determine if changing to clopidogrel will improve outcomes in S. aureus bacteremia in people who otherwise would have a reason to be taking it.
This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119).
If positive, this study will support a Phase 3 RCT in people who do not currently have an indication for clopidogrel.
Study sites(3)
NL and Labrador Health Services- Health Sciences Centre
St. John's, Newfoundland and Labrador, Canada
Recruiting
NL and Labrador Health Services- St. Clare's Mercy Hospital
St. John's, Newfoundland and Labrador, Canada
Recruiting
McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)
Montreal, Quebec, Canada
Recruiting
Showing 3 of 3 sites. 3 of the 3 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT06650488. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me